Type O red blood cells and AB plasma sit at the top of every blood bank’s wish list, and for different reasons. Type O red cells can be transfused to virtually any patient in an emergency, which means they are used disproportionately and run out first. AB plasma works the other way around, safe for recipients of any blood type, making it invaluable during massive bleeding events. Beyond these two workhorses, specific clinical situations create intense demand for rarer types and carefully matched units that most people never hear about.
Why Type O Red Cells Are Always Running Low
When a trauma patient arrives unconscious and bleeding, there is no time to draw blood, run a type-and-screen, and wait for matched units. The default protocol is to reach for type O packed red cells and start transfusing immediately. In the largest reported trauma series examining this practice, uncrossmatched type O red cells were available for transfusion 30 to 45 minutes sooner than type-specific or crossmatched blood, with no discernible increase in transfusion-related complications.1PubMed. Safety of uncrossmatched type-O red cells for resuscitation from hemorrhagic shock That speed matters when someone is losing blood faster than the lab can work. Every emergency department, every helicopter medevac, and every military field hospital stocks O units for exactly this scenario.
The catch is arithmetic. Roughly 45 percent of people in the United States have type O blood, yet type O red cells are pulled for every unknown patient, every emergency, and every situation where a mismatch could be fatal. That means consumption routinely outpaces the donor pool. Seasonal shortages make things worse: they most commonly hit during midsummer and early winter, driven by the combination of increased use of group O red cells and decreased donor availability during holidays and vacation periods.2PubMed Central. Seasonal blood shortages can be eliminated
Within type O, the Rh-negative subset (O negative) is under even more pressure. O-negative red cells are safe for any recipient regardless of Rh status, which makes them the first choice for women of childbearing age whose Rh type is unknown, since giving Rh-positive blood to an Rh-negative woman can trigger immune complications in future pregnancies. Trauma protocols reflect this: some centers stock O-positive units as the default but reserve O-negative specifically for women of childbearing age.1PubMed. Safety of uncrossmatched type-O red cells for resuscitation from hemorrhagic shock Only about 7 percent of the U.S. population is O negative, so the supply is thin to begin with.
AB Plasma Fills the Opposite Niche
For red blood cells, the universal donor is type O. For plasma, it flips: type AB is the universal donor. AB plasma lacks both anti-A and anti-B antibodies, so it can be given to patients of any ABO type without triggering a reaction. This makes it essential during massive transfusion events where the patient’s blood type is unknown and plasma needs to go in alongside red cells. Because AB is the rarest ABO group (around 4 percent of the U.S. population), blood banks frequently run out. High demand and a small donor pool create chronic supply problems, and researchers have explored whether low-titer A plasma might serve as a substitute in emergencies.3PubMed. Are there any alternatives for transfusion of AB plasma as universal donor in an emergency release setting?
Whole Blood Is Making a Comeback
For decades, donated blood has been separated into components: red cells, plasma, and platelets. That lets hospitals use each part where it is needed most. But in trauma resuscitation, patients often need all three at once, and reuniting the components at the bedside takes time and coordination. A growing number of trauma centers have started stocking low-titer group O whole blood, a product that contains red cells, plasma, fibrinogen, and platelets all in one bag. Because the anti-A and anti-B antibody levels are screened to be low, the whole blood can be given to non-O recipients with an acceptable safety margin.4PubMed Central. Trauma resuscitation with Low-Titer Group O Whole Blood Or Products: study protocol for a randomized clinical trial (the TROOP trial)
The practical appeal is straightforward: one bag instead of three means fewer steps, fewer checks, and faster flow from the decision to transfuse to the blood actually reaching the patient. Studies have shown reduced hands-on time and decreased workflow complexity. This shift has further increased demand for type O donors, particularly those with naturally low antibody titers who qualify to donate whole blood for trauma programs.
When the Common Types Are Not Enough
ABO and Rh get all the attention, but the surface of a red blood cell carries hundreds of other antigens. Most of the time, minor mismatches between donor and recipient go unnoticed. The problem arises when a patient’s immune system has been sensitized by previous transfusions or pregnancies and begins producing antibodies against antigens that almost everyone else has. At that point, the patient needs blood from a donor who also lacks those antigens, and such donors can be extraordinarily rare.
One dramatic example is the Bombay phenotype, in which a person lacks the H antigen that forms the foundation of the entire ABO system. Standard type O blood, which everyone assumes is universally safe, is actually incompatible with Bombay-phenotype recipients because their immune systems attack the H antigen itself. Finding a compatible donor means locating another Bombay-phenotype individual, which is vanishingly uncommon in most populations. Case reports describe surgical patients with the related para-Bombay phenotype facing dangerous delays because no compatible blood was available.5PubMed Central. Gynaecological Disorder with Rare Para-Bombay Phenotype: Challenge in Transfusion Support Rare donor registries exist specifically to coordinate these situations, connecting patients with donors across regions and even across countries when local supplies fall short.6PubMed. The silent threat: a true Bombay phenotype with unexpected tolerance to group O-positive incidental transfusion
An even rarer scenario is the Rhnull phenotype, sometimes called “golden blood,” in which a person’s red cells lack all Rh antigens. Fewer than 50 people worldwide have been identified with it. While Rhnull red cells can theoretically be given to anyone who has developed antibodies against common Rh antigens, the tiny number of potential donors means that finding compatible blood for an Rhnull patient who has been sensitized is a genuine crisis.7PubMed Central. First Report of Known Rare Rhnull Phenotype Individuals in Iran
Sickle Cell Disease and the Matching Problem
Patients with sickle cell disease often require chronic, repeated transfusions to manage their condition. Each transfusion exposes their immune system to donor antigens that may differ slightly from their own, and over time many of these patients develop antibodies that make future transfusions increasingly difficult. The risk of this immune sensitization, called alloimmunization, is especially high in sickle cell patients because the donor pool in many countries is predominantly of European descent, while sickle cell disease disproportionately affects people of African ancestry. The antigen profiles differ between these populations, so standard “compatible” blood by ABO and Rh standards can still provoke an immune response against other antigens.
The solution is more precise matching. Some transfusion programs now match donors and recipients on extended antigen panels that go well beyond ABO and Rh, including Kell, Duffy, Kidd, and MNS systems. In Brazil, a molecular matching program at three levels of stringency has shown clear clinical benefits: patients experienced higher hemoglobin levels after transfusion, lower percentages of sickle hemoglobin, better red cell survival in the body, and fewer transfusions overall.8PubMed Central. Optimized Antigen-Matched in Sickle Cell Disease Patients: Chances and Challenges in Molecular Times – the Brazilian Way The challenge is that this kind of matching requires a diverse donor pool. If most donors are from one ethnic background, finding extended-match-compatible units for patients from another background gets progressively harder.
The Donor Pool Does Not Mirror the Patient Pool
One underappreciated driver of blood shortages is the mismatch between who donates and who needs blood. Donor populations in many countries tend to skew toward certain demographics, with trends showing underrepresentation of young men and ethnic minorities.9ISBT Science Series. The relation between blood donor recruitment and donor diversity and loyalty in the Netherlands That matters because blood type distributions vary across ethnic groups. A large study comparing donor and patient blood-type distributions in China found statistically significant mismatches: for instance, the proportion of A-positive and B-positive blood among patients was higher than among donors, while O-positive was slightly more common in the donor pool than in the patient population. The gap was even more pronounced for rare Rh-negative subtypes, where certain types appeared at twice the frequency in patients as in donors.10PubMed Central. ABO and RhD blood group distributions in Gansu Province, China: A retrospective study based on donor and patient data
These mismatches mean that overall donation numbers can look adequate while specific types remain in deficit. A blood bank with a full shelf of A-positive units and an empty shelf of B-negative units is not a well-stocked blood bank. Targeted donor recruitment, particularly among underrepresented communities, is one of the few practical levers blood services have to close these gaps.
Platelets and the Shelf-Life Squeeze
Red cells get the most public attention, but platelets are arguably the more fragile part of the blood supply. Red cell units can be refrigerated for weeks. Platelets, by contrast, must be stored at room temperature with constant gentle agitation and expire quickly. In many countries, the maximum shelf life is only four to five days. That razor-thin window means that even modest fluctuations in donation rates or hospital demand can tip a blood bank from adequate supply to shortage overnight.
Modeling studies have shown that extending platelet shelf life by even one or two days would dramatically reduce shortages. At one modeled production level, moving from a four-day to a five-day shelf life cut the shortage rate from about 2.8 percent to 0.7 percent, and going to six or seven days nearly eliminated shortages altogether, including for rare blood types.11PubMed Central. Impact of Shelf-Life Extension on Platelet Availability: Results from an Inventory Management Modeling Study Some jurisdictions have already moved to a five-day or seven-day limit with pathogen-reduction treatment, but adoption is uneven.
Cancer patients undergoing chemotherapy are among the heaviest consumers of platelets, and those who receive many transfusions can develop antibodies against donor immune markers, making them refractory to standard platelet products. These patients need HLA-matched platelets from donors whose tissue type closely matches their own, adding yet another layer of specificity to the demand picture.
Pregnancy, Rh Factor, and a Preventable Crisis
When an Rh-negative mother carries an Rh-positive baby, small amounts of fetal blood can cross into her circulation and trigger an immune response. Her body produces anti-D antibodies that, in a subsequent Rh-positive pregnancy, can cross the placenta and attack the baby’s red cells, causing hemolytic disease of the fetus and newborn. This was once a major cause of stillbirth and severe newborn anemia.
The preventive treatment, Rh immunoglobulin (commonly known by the brand name RhoGAM), is given to Rh-negative mothers at 28 weeks and again within 72 hours after delivery if the baby is Rh-positive. This regimen reduces the risk of Rh sensitization from roughly 13 to 16 percent down to 0.1 to 0.2 percent.12Journal of Patient Safety and Risk Management. Consequences of erroneous reporting and interpretation of positive antibody screen in Rhesus (Rh) negative pregnancy: A report of two cases It is one of the great success stories in transfusion medicine, but it depends on accurate blood typing and follow-through.
The issue also intersects with trauma care. If an Rh-negative woman of childbearing age receives Rh-positive type O red cells during emergency resuscitation, she can become sensitized. A study of pregnant women who had developed immune-stimulated anti-D found that in 62 percent of those pregnancies the antibody titer reached levels associated with significant fetal risk.13PubMed Central. Another piece of the hemolytic disease of the fetus and newborn puzzle after RhD-positive transfusion in trauma resuscitation: the proportion of pregnant women who produce high titer anti-D This is why trauma protocols specifically set aside O-negative units for women in their reproductive years, even though O-positive would otherwise be acceptable for emergency use.
Special Demands for Newborns
Premature infants who need transfusions present their own set of requirements. Their immature immune systems are especially vulnerable to infections transmitted through blood products, with cytomegalovirus (CMV) being a particular concern. CMV is common in the adult population and rarely causes problems in healthy adults, but it can be devastating in preterm neonates. Research has long recommended that all premature infants requiring transfusion receive blood from donors who test negative for CMV antibodies, regardless of whether the infant’s mother has been exposed to the virus.14PubMed. Acquisition of cytomegalovirus infection by premature neonates An alternative approach is to filter white cells out of the donated blood, since CMV hides inside white blood cells rather than in the red cells or plasma themselves.15PubMed. Prevention of transfusion-associated cytomegalovirus infection in neonatal patients by the removal of white cells from blood
These extra screening and processing requirements narrow the eligible donor pool further. A CMV-negative, O-negative, irradiated red cell unit suitable for a premature baby is a much more constrained product than a standard unit of red cells for an adult surgical patient. Neonatal units at major hospitals maintain dedicated inventories for exactly this reason.
Turning A and B Into O
One of the more exciting lines of research in transfusion medicine aims to sidestep the whole supply problem by converting non-O blood into universal-donor blood. The idea is conceptually simple: the A and B blood types are defined by specific sugar molecules sitting on the red cell surface. Strip those sugars off with the right enzyme, and you are left with a cell that looks like type O to the recipient’s immune system.16PubMed Central. Toward universal donor blood: Enzymatic conversion of A and B to O type
The practical obstacle has been efficiency. Early enzymes worked but required large quantities and long incubation times, making the process impractical at scale. More recent work has identified pairs of bacterial enzymes that work together far more effectively. A 2025 study characterized two enzymes from the gut bacterium Flavonifractor plautii that act in sequence: one strips off a chemical group from the A-type sugar, and the second cleaves the remaining structure. Together, they convert A-type red cells to O-type with much higher efficiency than earlier approaches.17PubMed Central. Structural basis of FpGalNase and its combination with FpGalNAcDeAc for efficient A-to-O blood group conversion If this technology matures to clinical use, it could dramatically ease the pressure on type O donors by unlocking the A, B, and AB supply for universal use.
Lab-Grown Red Blood Cells
An even more ambitious approach is growing red blood cells from stem cells in the laboratory. In principle, this would allow blood banks to produce any blood type on demand, including rare phenotypes that are almost impossible to source from volunteer donors. Early proof-of-concept work has demonstrated that functional red cells can be cultured from stem cells, and the technology is slowly maturing.18PubMed Central. Concise review: production of cultured red blood cells from stem cells A small clinical trial in the UK in 2022 transfused lab-grown red cells into healthy volunteers for the first time, confirming that the cells survived in circulation.
The gap between a proof-of-concept transfusion and a scalable manufacturing process remains vast. A single standard unit of red cells contains about a trillion cells. Current lab methods can produce meaningful quantities but at costs and timescales that are nowhere near competitive with volunteer donation. For the foreseeable future, lab-grown blood is most likely to fill niches where no alternative exists, such as patients with ultra-rare phenotypes like Bombay or Rhnull, rather than replacing the general blood supply.
Why Blood Types Exist at All
The global distribution of ABO blood types is not random, and researchers have long suspected that infectious diseases shaped it through natural selection. The strongest evidence involves malaria. Studies have shown that blood group O provides meaningful protection against severe falciparum malaria, the deadliest form of the disease, through a specific mechanism: the malaria parasite causes infected red cells to stick to uninfected ones in clumps called rosettes, which clog small blood vessels. Type O red cells form rosettes less readily than types A, B, or AB.19PubMed Central. Blood group O protects against severe Plasmodium falciparum malaria through the mechanism of reduced rosetting
This selective advantage helps explain why type O is especially common in regions with historically high malaria burden, such as sub-Saharan Africa and parts of Central and South America. The non-O blood groups, meanwhile, appear to have been maintained because they confer advantages against other selective pressures, possibly including susceptibility to different pathogens like cholera or plague. The overall picture is one of balancing selection, where no single blood type wins everywhere because the disease landscape varies by region.20PubMed Central. Blood groups and malaria: fresh insights into pathogenesis and identification of targets for intervention That ancient evolutionary tug-of-war is the reason blood banks today face the inventory puzzle they do: humanity settled on a mix of types rather than converging on one.